Royalty Pharma plc (RPRX) Fair Value 2026

RPRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.1 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-28, Royalty Pharma plc (RPRX) trades at $60.85, versus a $30.57 median fair value across its 9 active models — 49.8% below the current price. QOC: 8.1/10. Value Trap Risk: 24/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $115.89.

Key Facts

Ticker
RPRX
Price
$60.85
Quality Score
8.1/10
Value Trap Risk
24/100
Models Active
9/13
Last Updated
Strength: Bayesian DCF suggests +90.4% upside with 64% confidence
Risk: Majority of models suggest overvaluation

Is Royalty Pharma plc (RPRX) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Royalty Pharma plc (RPRX) appears overvalued as of : the median of 9 independent fair value estimates is $30.57, 49.8% below the current price of $60.85. Estimates range from $16.78 to $115.89. RPRX scores 8.1/10 on fundamental quality and 24/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. RPRX’s -49.8% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Royalty Pharma plc Stock in 2026? →

What Fair Value Does Each Model Give RPRX?

9 Intrinsic Value Models vs. Current Price ($60.85)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $115.89 +90.4%
Intrinsic · High Conviction
 $16.78 -72.4%
Ensemble · Low Conviction
 $40.67 -33.2%
Intrinsic · High Conviction
 $20.37 -66.5%
Unlock the Full Matrix

Access 5 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is RPRX's Fair Value Range?

Spread across 9 independent models · $16.78 to $115.89

CirclFi's 9 active models place Royalty Pharma plc (RPRX) between $16.78 and $115.89 per share, a spread of 324% of the median. The median of that range — $30.57 — is the fair value CirclFi publishes for RPRX, against a current price of $60.85.

Low · EPVHigh · Bayesian DCF
$16.78median $30.57$115.89
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$16.78
Most bullish modelBayesian DCF$115.89
Model agreement2 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for RPRX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on RPRX, not a CirclFi price target. How each model works →

What Is Royalty Pharma plc (RPRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Royalty Pharma plc's intrinsic value is estimated at $30.57. Trading at its current price of $60.85, the valuation engine raises significant caution: 7 of 9 models flag downside risk, projecting a median implied return of -49.8%. Model dispersion is worth noting: Bayesian DCF targets $115.89 (+90.4%), versus EPV at $16.78 (-72.4%). This +162.9% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About RPRX?

9 of 13 models are currently active for RPRX. Of these, 2 models suggest upside while 7 models suggest overvaluation. Taken together, their median fair value for RPRX is $30.57 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $115.89 on its own, implying +90.4% upside from the current price. See which stocks rank higher →

How Does RPRX Rank in Biotechnology?

Among 625 Biotechnology stocks, RPRX ranks #29 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places RPRX in the top tier.

See all Most Undervalued Biotechnology Stocks →

Royalty Pharma plc's positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is RPRX a Value Trap?

CirclFi's Value Trap algorithm assigns RPRX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Royalty Pharma plc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Royalty Pharma plc earns a quality score of 8.1/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +162.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RPRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RPRX's 9 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Royalty Pharma plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

VXRTVaxart, Inc.QOC 8.1LGNDLigand Pharmaceuticals IncorporatedQOC 7.9TGTXTG Therapeutics, Inc.QOC 8.1KRYSKrystal Biotech, Inc.QOC 7.8KROSKeros Therapeutics, Inc.QOC 8.2NVAXNovavax, Inc.QOC 7.7MGXMetagenomi Therapeutics, Inc.QOC 5.7EMMAEmmaus Life Sciences, Inc.QOC 4.9DCOYDecoy Therapeutics Inc.QOC 4.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: VXRT · LGND · TGTX · KRYS · KROS · NVAX · MGX · EMMA · DCOY · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RPRX?

6 companies across all industries closest to RPRX’s Quality of Company score of 8.1/10.

CXDOCrexendo, Inc.QOC 8.1UGUnited-Guardian, Inc.QOC 8.1FNRNFirst Northern Community BancorpQOC 8.1FOURShift4 Payments, Inc.QOC 8.1CDWCDW CorporationQOC 8.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CXDO · UG · FNRN · FOUR · CDW · NVDA

Where Does RPRX Sit in CirclFi's Biotechnology Rankings?

RPRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Royalty Pharma plc’s Valuation?

What is Royalty Pharma plc's intrinsic value in 2026?

CirclFi puts Royalty Pharma plc (RPRX)'s intrinsic value at $30.57 — the median of 9 independent model estimates as of 2026-08-28, ranging from $16.78 to $115.89. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $115.89 on its own. The Quality of Company score is 8.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RPRX overvalued or undervalued right now?

At $60.85, 2 of 9 active models suggest RPRX may be undervalued, while 7 indicate potential overvaluation. The median of all 9 fair value estimates is $30.57, 49.8% below the current price of $60.85 — a consensus view that RPRX is overvalued. The assessment depends on which methodology best fits Royalty Pharma plc's business model in Biotechnology.

What does a Quality of Company score of 8.1 mean for RPRX?

Royalty Pharma plc's QOC of 8.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on RPRX?

CirclFi analyzes RPRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on RPRX?

Of the 9 models currently active on RPRX, Bayesian DCF is the most bullish at $115.89 per share, and Earnings Power Value (EPV) is the most bearish at $16.78. CirclFi's published fair value for RPRX is the median of that range, $30.57, not either extreme. The gap between the two ends equals 324% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is RPRX a value trap in 2026?

Royalty Pharma plc's Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Royalty Pharma plc (RPRX) has a median fair value of $30.57 — 49.8% below the current price of $60.85 — as of 2026-08-28.” Source: circlfi.com/stock/RPRX/ · Methodology
Primary sources for this RPRX valuation
  • Financial statements: Royalty Pharma plc 10-K and 10-Q filings on SEC EDGAR (CIK 0001802768) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RPRX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on RPRX.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for RPRX Unlock All 9 — $39/mo